Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03933319
- Locations
- 🇨🇳
Peng Yuan, Beijing, Beijing, China
A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03933982
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
- Conditions
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03927898
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT03923166
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT03923179
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT03915132
- Locations
- 🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijin, China
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT03916913
- Locations
- 🇨🇳
Cancer Hospital/Institute, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT03908372
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijin, China
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT03876886
- Locations
- 🇨🇳
National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Optical Assessment on Brain Death Via a Oxygen Supply Procedure
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT03864887
- Locations
- 🇨🇳
NIRS assessment for brain death, Tianjin, Tianjin, China